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Background and aims
Clinical observations suggest that the use of non-steroi-
dal anti-inflammatory drugs (NSAIDs) for symptomatic
treatment of headache is not in line with recommenda-
tions by international guidelines [1]. The aim of the
study was to evaluate NSAIDs use for episodic headache
at the Headache Centre of the Chieti University in the
period: January 2000-February 2013.
Methods
A retrospective evaluation was carried out on 6,443
records of episodic migraine (n=2,330), tension-type
headache (TTH) (n=807) and migraine + TTH
(n=3,306) sufferers relative to NSAID use for the acute
attack: type of NSAID/s; uni- or poly-therapy (one or
more NSAID/s in different attacks) and NSAID efficacy
(subjective scale: complete (C), partial (P) or absent (A)
pain relief at 2 hours), at the first visit and 1-year fol-
low-up.
Results
In migraine patients, 80% had been NSAID users in the
past year. The three most frequently employed mole-
cules were: nimesulide (57%), ketoprofen (25%) and ibu-
profen (24%). Complete vs. incomplete/absent efficacy
was significantly higher for all three (p < 0.0001).
NSAIDs were replaced with triptans in 53% of the
patients at the first visit; after 1 year: a significant spon-
taneous return to NSAIDs occurred in 56% of the cases
(p < 0.0005) for inadequate efficacy/side effects (62%) or
difficulty in obtaining prescription (38%) of triptans
from the family doctor. In TTH patients, 90% were
NSAID users; preferences were: nimesulide (48%), keto-
profen (47%) and diclofenac (19%); complete vs. incom-
plete/absent efficacy was significantly higher for the first
two (p < 0.02). Replacement with analgesics was per-
formed in 24% of the patients at the first visit; at one-
year follow-up a spontaneous return to NSAIDs
occurred in 29% of the cases for inadequate efficacy of
the non-NSAID therapy. In Migraine + TTH patients
who were not able to distinguish the nature of their
attack at the beginning of the pain, 89% were NSAID
users; the three most frequently employed molecules
were: nimesulide (44%), ibuprofen (42%) and ketoprofen
(38%); complete vs. incomplete/absent efficacy was sig-
nificantly higher for all three (0.001 < p < 0.0001).
Replacement with analgesics was prescribed to 31% of
the patients at the first visit; at one-year follow-up a
spontaneous return to NSAIDs occurred in 37% of them
for inadequate efficacy of the non-NSAID therapy.
Conclusions
NSAID use in episodic headache is higher than could be
hypothesized based on guidelines [2]. NSAID role/efficacy,
particularly in migraine, should be better understood. A
higher degree of sensitization towards different treatment
options for headache should also be promoted in the med-
ical environment [3].
Written informed consent to publish was obtained
from the patient(s).
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